AstraZeneca has already paused or scrapped investments worth hundreds of millions of pounds, citing a cut in British government support
British-Swedish pharmaceutical multinational AstraZeneca could halt further investment in the UK unless the government reforms its drug pricing policies, the company’s local chairman has said, as cited by The Telegraph. The pharma giant has already delayed or abandoned projects worth hundreds of millions of pounds, citing an increasingly unattractive commercial environment in the country.
Shaun Grady pointed to what he called an outdated and restrictive pricing system used by the National Health Service…
Read the full article at RT.COM
